| # | Drug | Count |
|---|---|---|
| 0 | OXALIPLATIN | 8 |
| 1 | BEVACIZUMAB | 6 |
| 2 | FLUOROURACIL | 6 |
| 3 | FLUOROURACIL CREAM, 0.5% | 6 |
| 4 | MERCAPTOPURINE | 6 |
| 5 | INFLIXIMAB | 5 |
| 6 | FUROSEMIDE | 4 |
| 7 | IBUPFROFEN | 4 |
| 8 | IBUPROFEN | 4 |
| 9 | IBUPROFEN 200 MG | 4 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | PSYLLIUM HUSK | 1 | 0.0007 |
| 1 | RADIUM RA 223 DICHLORIDE | 3 | 0.0006 |
| 2 | MERCAPTOPURINE | 6 | 0.0003 |
| 3 | KETAMINE HYDROCHLORIDE | 1 | 0.0002 |
| 4 | DAROLUTAMIDE | 1 | 0.0002 |
| 5 | ACETAZOLAMIDE SODIUM | 1 | 0.0002 |
| 6 | PRAZOSIN | 1 | 0.0002 |
| 7 | ERTAPENEM SODIUM | 1 | 0.0001 |
| 8 | BUPIVACAINE HYDROCHLORIDE IN DEXTROSE | 1 | 0.0001 |
| 9 | QUINAPRIL HYDROCHLORIDE | 1 | 0.0001 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Cannabinoid [EPC] | 1 | 0.0001 |
| 1 | SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC] | 1 | 0.0001 |
| 2 | Provitamin D2 Compound [EPC] | 2 | 0.0001 |
| 3 | Carbonic Anhydrase Inhibitor [EPC] | 1 | 0.0000 |
| 4 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 1 | 0.0000 |
| 5 | Epidermal Growth Factor Receptor Antagonist [EPC] | 2 | 0.0000 |
| 6 | Aluminum Complex [EPC] | 1 | 0.0000 |
| 7 | Androgen Receptor Inhibitor [EPC] | 3 | 0.0000 |
| 8 | Gonadotropin Releasing Hormone Receptor Antagonist [EPC] | 1 | 0.0000 |
| 9 | Central alpha-2 Adrenergic Agonist [EPC] | 2 | 0.0000 |